Mangoceuticals, Inc.
MGRX· Nasdaq
MGRXMangoceuticals, Inc.
Filed May 15, 2024 · 10-Q · 45 days after period end · 0001493152-24-019960
| Metric | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|
| Revenue | $214.10K | $100.72K | — |
| Net Income | -$2.37M | -$2.56M | -$19.60K |
| EPS Diluted | -$1.50 | -$0.23 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Mangoceuticals, Inc. · CIK 1938046 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 15, 2024 · 45 d after period end
